Hinova Pharma is an international, clinical-stage pharmaceutical company dedicated to developing innovative therapeutics for cancer and metabolic syndromes. The company leverages advanced technologies such as PROTAC (Proteolysis Targeting Chimeras) and deuteration to create best-in-class and first-in-class drugs. Hinova Pharma operates in the global pharmaceutical market, serving patients who require effective, safe, and affordable medications for serious health conditions. The business model is centered around research and development (R&D), with four core R&D platforms: PROTAC Platform, Deuteration Platform, Novel Target Discovery and Validation Platform, and Translational Medical Technology Platform. These platforms enable the company to discover, develop, and bring to market novel therapeutics. Hinova Pharma generates revenue through the development and commercialization of its proprietary drugs, as well as through strategic collaborations and partnerships. The company has submitted over 200 PCT and national patents, with more than 90 patents granted globally, including in the US, EU, and Japan. Hinova Pharma's flagship product, HC 1119, a deuterated compound of enzalutamide, is currently undergoing Phase III clinical trials and has shown potential for higher safety and efficacy.

Keywords: PROTAC, deuteration, oncology, metabolic syndrome, clinical trials, innovative drugs, R&D platforms, global patents, HC 1119, pharmaceutical.